The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 39.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.597%)
Open: 39.00
High: 39.00
Low: 39.00
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

12 Jul 2017 07:00

RNS Number : 7615K
Venture Life Group PLC
12 July 2017
 

12 July 2017

Venture Life Group plc

("Venture Life" or "the Group")

 

Trading update for the 6 months ended 30 June 2017

28% growth in revenues

 

Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, today provides a trading update for the six months ended 30 June 2017. 

 

· Unaudited revenues for the six months ended 30 June 2017 were £7.8m, 28% higher than the same period last year (H1 2016: £6.1m)

· On a like for like basis (including a full 6 months of Periproducts revenues for H1 2016) this is growth of 18% over H1 2016

· Periproducts (UltraDEX UK) recorded its highest month of revenue in June for at least the last 5 years

· Record month in Biokosmes as it recorded its largest ever revenue for a single month in June

· 4 new deals signed internationally, including one on UltraDEX

 

June has seen the second UltraDEX promotional campaign in 2017 in the UK, which included TV advertising and promotions through independent coffee shops amongst other activities. July will also see the launch of the newly refreshed range of packaging in our major pharmacy partner, along with the launch of the UltraDEX sensitive range and new one litre packs sizes. There was also confirmation in the first half of the year that store penetration will increase (taking effect in July 2017), with 1,503 new listings of UltraDEX in stores across the UK with our major pharmacy partner.

 

Commenting, Chief Executive Officer, Jerry Randall, said: "The first half of 2017 has shown continued growth and momentum in the business. The UltraDEX acquisition is now fully integrated and delivering the synergies and profitability expected. It is also attracting good interest internationally. This has validated our decision to make the acquisition and also proves the model we have for utilising the good operational leverage that we have which is available for future acquisitions. I am delighted with the continued organic growth of the business in challenging markets and in particular, that we have delivered a record level of sales during June in both Biokosmes, and UltraDEX."

 

 

For further information please contact:

 

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton / Margarita Mitropoulou (Corporate Finance)

Bob Pountney / John Howes (Corporate Broking) 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope / Ben Turner

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Paul McManus / Anna Dunphy

+44 (0) 7980 541 893 / +44 (0) 7876 741 001

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKDDPQBKDPOD
Date   Source Headline
8th Dec 202012:00 pmRNSResult of General Meeting and Open Offer
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results
25th Mar 20207:00 amRNSNotice of Results Update and Trading Update
9th Mar 20207:00 amRNSTrading Update and Notice of Results
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Jan 202012:37 pmRNSCompletion of Acquisition
9th Jan 20204:28 pmRNSDirector/PDMR Shareholding
6th Jan 20203:38 pmRNSGrant of Options
19th Dec 20197:00 amRNSAcquisition and Trading Update
18th Nov 20192:02 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.